Exchange: NYSE·Updated 07:52 PM EDT

BSX News

News
all
press releases
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Zacks
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Zacks
More News
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.
Zacks
New Strong Sell Stocks for October 30th
BSX, NBHC and NMRK have been added to the Zacks Rank #5 (Strong Sell) List on October 30th, 2026.
Zacks
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Penumbra, Inc. Reports Third Quarter 2026 Financial Results Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsPR NewswireALAMEDA, Calif., Oct. 29, 2026 ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN), the world's leading thrombectomy company, today reported...
PR Newswire
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?
Intuitive Surgical's third-quarter sales surged 22%, outpacing procedure growth. Can system placements, new technologies and recurring revenues offset pricing pressures?
Zacks
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
Zacks
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.read more...
Benzinga
BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook
Boston Scientific’s weak outlook, cyberattack disruptions, and slowing Watchman and electrophysiology growth weighed on sentiment.
Stocktwits
Boston Scientific (BSX) Q3 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Boston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares.
Zacks

Advertisement|Remove ads.